A Potential Role of Ruxolitinib in Leukemia

Expert Opinion on Investigational Drugs - United Kingdom
doi 10.1517/13543784.2011.589383
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Activity of the Janus Kinase Inhibitor Ruxolitinib in Chronic Lymphocytic Leukemia: Results of a Phase II Trial

Haematologica
Hematology
2016English

Critical Appraisal of the Role of Ruxolitinib in Myeloproliferative Neoplasm-Associated Myelofibrosis

OncoTargets and Therapy
OncologyPharmacology
2015English

Potential for Bispecific T-Cell Engagers: Role of Blinatumomab in Acute Lymphoblastic Leukemia

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2016English

MicroRNA-155 Regulates Casein Kinase 1 Gamma 2: A Potential Pathogenetic Role in Chronic Lymphocytic Leukemia

Blood Cancer Journal
OncologyHematology
2017English

Identification of RNPC3 as a Novel JAK2 Fusion Partner Gene in B‐acute Lymphoblastic Leukemia Refractory to Combination Therapy Including Ruxolitinib

Molecular genetics & genomic medicine
GeneticsMolecular Biology
2019English

Histone-Modifying Enzymes: Their Role in the Pathogenesis of Acute Leukemia and Their Therapeutic Potential

International Journal of Hematology
Hematology
2013English

Elf-2, a Rhombotin-2 Binding Ets Transcription Factor: Discovery and Potential Role in T Cell Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1997English

Treatment-Related Acute Myeloid Leukemia in a Chronic Lymphocytic Leukemia Patient: Role of Fludarabine?

Therapeutic Advances in Hematology
Hematology
2015English

Potential Role of Selection Bias in the Association Between Childhood Leukemia and Residential Magnetic Fields Exposure: A Population-Based Assessment

Cancer Epidemiology
Cancer ResearchEpidemiologyOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy